Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00578877 · ClinicalTrials.gov registry record · Phase 2
Contraceptive Effectiveness and Safety of the SILCS Diaphragm
A Phase 2 study, sponsored by CONRAD.
- Completed
- Registry status
- Phase 2
- Development phase
- 450
- Enrollment target
NCT00578877: Completed Phase 2 study, sponsored by CONRAD.
NCT00578877 is a Phase 2 study that has completed, run by CONRAD. The registered enrollment target is 450 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (238% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00578877, a Phase 2 study, has completed, sponsored by CONRAD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 450 participants
- Enrollment target
Study Summary
This multi-center contraceptive effectiveness and safety study of the SILCS diaphragm will enroll approximately 450 couples at risk for pregnancy at six study sites in the U.S. The study will randomly assign approximately 300 couples to use the SILCS diaphragm with BufferGel and approximately 150 couples to use the SILCS diaphragm with Gynol II (2% N-9 gel). At two sites, a substudy involving colposcopy and microflora will be conducted in about 80 women (40 at each site). The primary objective of this study is to estimate the cumulative 6-month typical-use pregnancy probability for women using the SILCS diaphragm with a contraceptive gel.
Interventions
- DEVICE SILCS Diaphragm
- COMBINATION_PRODUCT Nonoxynol-9 Gel
- COMBINATION_PRODUCT Buffer Gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2008-01 |
| Est. Completion | 2009-11 |
| Phase | Phase 2 |
What the finished NCT00578877 record still lists
NCT00578877 is an interventional study that assigns participants to a tested intervention. The registered 450 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (238% higher).
The record links to 0 conditions, and to 3 interventions - of which SILCS Diaphragm is the first listed.
NCT00578877 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00578877 about?
NCT00578877 is a clinical study titled "Contraceptive Effectiveness and Safety of the SILCS Diaphragm". This multi-center contraceptive effectiveness and safety study of the SILCS diaphragm will enroll approximately 450 couples at risk for pregnancy at six study sites in the U.S. The study will randomly assign approximately 300 couples to use the SILCS diaphragm with BufferGel and approximately 150 co...
What is the current status of trial NCT00578877?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 450 participants. The study started on 2008-01. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00578877?
The interventions under investigation include: SILCS Diaphragm (DEVICE), Nonoxynol-9 Gel (COMBINATION_PRODUCT), Buffer Gel (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT00578877?
This trial is sponsored by CONRAD, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00578877's enrollment target sits among peer trials
450 87th of 2000 higher than 1,912 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00515060 · 450 participants
Psychophysical Studies of Cancer Therapy Pain
- NCT01257269 · 450 participants
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
- NCT03047161 · 450 participants
Electrophysiology of Fetal Arrhythmia
- NCT03269630 · 450 participants
New Orleans Pulmonary Hypertension Biobank
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia